{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:13:39Z","timestamp":1777472019552,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s00280-010-1467-x","type":"journal-article","created":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T09:36:59Z","timestamp":1285839419000},"page":"1005-1012","source":"Crossref","is-referenced-by-count":8,"title":["Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer"],"prefix":"10.1007","volume":"66","author":[{"given":"Nancy","family":"Egerton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,1]]},"reference":[{"issue":"6","key":"1467_CR1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7164\/antibiotics.49.560","volume":"49","author":"K Gerth","year":"1996","unstructured":"Gerth K, Bedorf N, Hofle G, Irschik H, Reichenbach H (1996) Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 49(6):560\u2013563","journal-title":"J Antibiot (Tokyo)"},{"issue":"11","key":"1467_CR2","first-page":"2325","volume":"55","author":"DM Bollag","year":"1995","unstructured":"Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J et al (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55(11):2325\u20132333","journal-title":"Cancer Res"},{"issue":"1","key":"1467_CR3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00280-008-0724-8","volume":"63","author":"FY Lee","year":"2008","unstructured":"Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R et al (2008) Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 63(1):157\u2013166","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1467_CR4","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1073\/pnas.040546297","volume":"97","author":"P Giannakakou","year":"2000","unstructured":"Giannakakou P, Gussio R, Nogales R, Downing KH, Zaharevitz D, Bollbuck B et al (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci 97(6):2904\u20132909","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"1467_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568011023354290","volume":"2","author":"MA Jordan","year":"2002","unstructured":"Jordan MA (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2(1):1\u201317","journal-title":"Curr Med Chem Anticancer Agents"},{"issue":"1","key":"1467_CR6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1568011023354489","volume":"2","author":"M Wartmann","year":"2002","unstructured":"Wartmann M, Altmann KH (2002) The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2(1):123\u2013148","journal-title":"Curr Med Chem Anticancer Agents"},{"issue":"1","key":"1467_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/1535-7163.MCT-08-0986","volume":"8","author":"C Dumontet","year":"2009","unstructured":"Dumontet C, Jordan MA, Lee FF (2009) Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 8(1):17\u201325","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"1467_CR8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1634\/theoncologist.2008-0143","volume":"13","author":"E Rivera","year":"2008","unstructured":"Rivera E, Lee J, Davies A (2008) Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 13(12):1207\u20131223","journal-title":"Oncologist"},{"issue":"7","key":"1467_CR9","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1345\/aph.1M005","volume":"43","author":"LB Michaud","year":"2009","unstructured":"Michaud LB (2009) The epothilones: how pharmacology relates to clinical utility. Ann Pharmacother 43(7):1294\u20131309","journal-title":"Ann Pharmacother"},{"key":"1467_CR10","unstructured":"Myers Squibb Company (2009) IXEMPRA\u00ae (ixabepilone) prescribing information. Bristol-Myers Squibb Company, Princeton, NJ"},{"key":"1467_CR11","first-page":"119","volume":"47","author":"FY Lee","year":"2006","unstructured":"Lee FY, Camuso A, Castaneda S, Fager K, Flefleh C, Inigo I et al (2006) Preclinical studies of ixabepilone (BMS-247550) demonstrate optimal antitumor activity against both chemotherapy-sensitive and -resistant tumor types. Proc Am Assoc Cancer Res 47:119 (Abstr 503)","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"10","key":"1467_CR12","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2004.12.001","volume":"22","author":"S Goodin","year":"2004","unstructured":"Goodin S, Kane MP, Rubin EH (2004) Epothilones: mechanism of action and biologic activity. J Clin Oncol 22(10):2015\u20132025","journal-title":"J Clin Oncol"},{"issue":"4","key":"1467_CR13","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1078-0432.CCR-0919-03","volume":"10","author":"S Mani","year":"2004","unstructured":"Mani S, McDaid H, Hamilton A, Hochster H, Cohen MB, Khabelle D et al (2004) Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 10(4):1289\u20131298","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1467_CR14","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/cncr.20977","volume":"103","author":"SH Zhuang","year":"2005","unstructured":"Zhuang SH, Agrawal M, Edgerly M, Bakke S, Kotz H, Thambi P et al (2005) A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3\u00a0days. Cancer 103(9):1932\u20131938","journal-title":"Cancer"},{"issue":"3","key":"1467_CR15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00280-008-0751-5","volume":"63","author":"A Awada","year":"2009","unstructured":"Awada A, Piccart MJ, Jones SF, Peck RA, Gil T, Lebwohl D et al (2009) Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard chemotherapy. Cancer Chemother Pharmacol 63(3):417\u2013425","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"1467_CR16","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2006.09.3849","volume":"25","author":"EA Perez","year":"2007","unstructured":"Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L et al (2007) Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25(23):3407\u20133414","journal-title":"J Clin Oncol"},{"issue":"23","key":"1467_CR17","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1200\/JCO.2006.08.9102","volume":"25","author":"E Thomas","year":"2007","unstructured":"Thomas E, Tabernero J, Fornier M, Conte P, Fumoleau P, Lluch A et al (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25(23):3399\u20133406","journal-title":"J Clin Oncol"},{"issue":"23","key":"1467_CR18","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1200\/JCO.2006.09.7535","volume":"25","author":"H Roche","year":"2007","unstructured":"Roche H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J et al (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25(23):3415\u20133420","journal-title":"J Clin Oncol"},{"issue":"23","key":"1467_CR19","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.2006.10.0784","volume":"25","author":"N Denduluri","year":"2007","unstructured":"Denduluri N, Low JA, Lee JJ, Berman AW, Walshe JM, Vatas U et al (2007) Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 25(23):3421\u20133427","journal-title":"J Clin Oncol"},{"issue":"12","key":"1467_CR20","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2005.10.024","volume":"23","author":"JA Low","year":"2005","unstructured":"Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX et al (2005) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23(12):2726\u20132734","journal-title":"J Clin Oncol"},{"issue":"1","key":"1467_CR21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10637-006-9006-7","volume":"25","author":"N Denduluri","year":"2007","unstructured":"Denduluri N, Lee JJ, Walshe J, Berman AW, Vatas U, Chow CK et al (2007) Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 25(1):63\u201367","journal-title":"Invest New Drugs"},{"issue":"24 Suppl","key":"1467_CR22","first-page":"856s","volume":"69","author":"JW Smith","year":"2009","unstructured":"Smith JW, Vukelja SJ, Rabe AC, Pluenneke RE, Wentworth-Hartung N, Benaderet LB et al (2009) Preliminary toxicity results of a phase II randomized trial of weekly or every-3-week ixabepilone in metastatic breast cancer (MBC). Cancer Res 69(24 Suppl):856s (Abstr 6099)","journal-title":"Cancer Res"},{"issue":"18S","key":"1467_CR23","first-page":"597s","volume":"24","author":"FY Lee","year":"2006","unstructured":"Lee FY, Camuso A, Castenada S, Flefleh C, Ingio I, Kan D et al (2006) Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J Clin Oncol 24(18S):597s (Abstr 12017)","journal-title":"J Clin Oncol"},{"issue":"3","key":"1467_CR24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3816\/CBC.2008.n.026","volume":"8","author":"C Bunnell","year":"2008","unstructured":"Bunnell C, Vahdat L, Schwartzberg L, Gralow J, Klimovsky J, Poulart V et al (2008) Phase I\/II study of ixabepilone plus capecitabine in anthracycline-pretreated\/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 8(3):234\u2013241","journal-title":"Clin Breast Cancer"},{"issue":"33","key":"1467_CR25","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","volume":"25","author":"ES Thomas","year":"2007","unstructured":"Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25(33):5210\u20135217","journal-title":"J Clin Oncol"},{"key":"1467_CR26","unstructured":"Hortobagyi GN, Perez EA, Vrdoljak E, Medina C, Xu B, Conte P et al (2008) Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trials. Presented at the American society of clinical oncology breast cancer symposium, Washington, DC, 5\u20137 Sept (Abstr 186)"},{"issue":"12","key":"1467_CR27","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","volume":"20","author":"J O\u2019Shaughnessy","year":"2002","unstructured":"O\u2019Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812\u20132823","journal-title":"J Clin Oncol"},{"key":"1467_CR28","doi-asserted-by":"crossref","unstructured":"Orsini L, Mukhopadhyay P, Peck R, Corey-Lisle P (2009) Quality adjusted time without symptoms or toxicities (Q-TWiST) of ixabepilone plus capecitabine versus capecitabine for metastatic breast cancer (MBC). Presented at the American society of clinical oncology breast cancer symposium, Orlando, FL, May 29\u2013June 2 (Abstr 170)","DOI":"10.1158\/0008-5472.SABCS-09-5051"},{"key":"1467_CR29","doi-asserted-by":"crossref","unstructured":"Orsini L, Mukhopadhyay P, Peck R, Corey-Lisle P (2009) Quality adjusted time without symptoms or toxicities (Q-TWiST) of ixabepilone (Ixa) plus capecitabine (cape) versus capecitabine for metastatic breast cancer (MBC) patients with poor prognostic features (PPF). Cancer Res 69:782s (Abstr 5051)","DOI":"10.1158\/0008-5472.SABCS-09-5051"},{"issue":"24","key":"1467_CR30","doi-asserted-by":"crossref","first-page":"8123","DOI":"10.1158\/1078-0432.CCR-08-0025","volume":"14","author":"FY Lee","year":"2008","unstructured":"Lee FY, Covello KL, Castaneda S, Hawken DR, Kan D, Lewin A et al (2008) Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res 14(24):8123\u20138131","journal-title":"Clin Cancer Res"},{"issue":"15S","key":"1467_CR31","first-page":"47s","volume":"27","author":"HS Rugo","year":"2009","unstructured":"Rugo HS, Campone M, Amadori D, Wardley A, Villa A, Conte PF et al (2009) Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa\/bev) versus paclitaxel plus bev (pac\/bev) as first-line therapy for metastatic breast cancer (MBC). J Clin Oncol 27(15S):47s (Abstr 1029)","journal-title":"J Clin Oncol"},{"issue":"15S","key":"1467_CR32","first-page":"128s","volume":"27","author":"PN Mainwaring","year":"2009","unstructured":"Mainwaring PN, Nguyen T, Price G, Venter D (2009) Ixabepilone and lapatinib for HER2-positive advanced breast cancer: preclinical rationale and phase I trial. J Clin Oncol 27(15S):128s (Abstr 2582)","journal-title":"J Clin Oncol"},{"issue":"4","key":"1467_CR33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/JCO.2007.14.2646","volume":"27","author":"J Baselga","year":"2009","unstructured":"Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG et al (2009) Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 27(4):526\u2013534","journal-title":"J Clin Oncol"},{"issue":"15S","key":"1467_CR34","first-page":"167s","volume":"27","author":"CE Horak","year":"2009","unstructured":"Horak CE, Lee FY, Xu L, Galbraith S, Baselga J et al (2009) High \u03b2-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: a retrospective analysis. J Clin Oncol 27(15S):167s (Abstr 3587)","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00280-010-1467-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T04:44:16Z","timestamp":1559709856000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1467-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,1]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["1467"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1467-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,1]]}}}